196 related articles for article (PubMed ID: 35247914)
1. Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma.
Javaid S; Schaefer A; Goodwin CM; Nguyen VV; Massey FL; Pierobon M; Gambrell-Sanders D; Waters AM; Lambert KN; Diehl JN; Hobbs GA; Wood KC; Petricoin EF; Der CJ; Cox AD
Mol Cancer Ther; 2022 May; 21(5):762-774. PubMed ID: 35247914
[TBL] [Abstract][Full Text] [Related]
2. Tipifarnib as a Precision Therapy for
Gilardi M; Wang Z; Proietto M; Chillà A; Calleja-Valera JL; Goto Y; Vanoni M; Janes MR; Mikulski Z; Gualberto A; Molinolo AA; Ferrara N; Gutkind JS; Burrows F
Mol Cancer Ther; 2020 Sep; 19(9):1784-1796. PubMed ID: 32727882
[TBL] [Abstract][Full Text] [Related]
3. Evolutionary dynamics of tipifarnib in HRAS mutated head and neck squamous cell carcinoma.
Jagadeeshan S; Suryamohan K; Shin N; Mathukkada S; Boyko A; Melikhova D; Tsareva A; Yunusova L; Pravdivtseva E; Stupichev D; Shaposhnikov K; Peterson A; Bednyagin L; Shugaev-Mendosa E; Kessler L; Burrows F; Ho AL; Agrawal N; Pearson AT; Izumchenko E; Cole G; Elkabets M; Rosenberg AJ
Oral Oncol; 2024 Feb; 149():106688. PubMed ID: 38219706
[TBL] [Abstract][Full Text] [Related]
4. Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity.
Smith AE; Chan S; Wang Z; McCloskey A; Reilly Q; Wang JZ; Patel HV; Koshizuka K; Soifer HS; Kessler L; Dayoub A; Villaflor V; Adkins DR; Bruce JY; Ho AL; Perez CA; Hanna GJ; Gascó Hernández A; Saunders A; Dale S; Gutkind JS; Burrows F; Malik S
Cancer Res; 2023 Oct; 83(19):3252-3263. PubMed ID: 37339176
[TBL] [Abstract][Full Text] [Related]
5. Tipifarnib in Head and Neck Squamous Cell Carcinoma With
Ho AL; Brana I; Haddad R; Bauman J; Bible K; Oosting S; Wong DJ; Ahn MJ; Boni V; Even C; Fayette J; Flor MJ; Harrington K; Kim SB; Licitra L; Nixon I; Saba NF; Hackenberg S; Specenier P; Worden F; Balsara B; Leoni M; Martell B; Scholz C; Gualberto A
J Clin Oncol; 2021 Jun; 39(17):1856-1864. PubMed ID: 33750196
[TBL] [Abstract][Full Text] [Related]
6.
Coleman N; Marcelo KL; Hopkins JF; Khan NI; Du R; Hong L; Park E; Balsara B; Leoni M; Pickering C; Myers J; Heymach J; Albacker LA; Hong D; Gillison M; Le X
JCO Precis Oncol; 2023 Jan; 7():e2200211. PubMed ID: 36603172
[TBL] [Abstract][Full Text] [Related]
7. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
Ruicci KM; Pinto N; Khan MI; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
Oral Oncol; 2018 Sep; 84():95-103. PubMed ID: 30115483
[TBL] [Abstract][Full Text] [Related]
8. Targeting HRAS in Head and Neck Cancer: Lessons From the Past and Future Promise.
Desilets A; Ho AL
Cancer J; 2022 Sep-Oct 01; 28(5):363-368. PubMed ID: 36165724
[TBL] [Abstract][Full Text] [Related]
9. Mutant HRas Signaling and Rationale for Use of Farnesyltransferase Inhibitors in Head and Neck Squamous Cell Carcinoma.
Wang J; Al-Majid D; Brenner JC; Smith JD
Target Oncol; 2023 Sep; 18(5):643-655. PubMed ID: 37665491
[TBL] [Abstract][Full Text] [Related]
10. Targeting Harvey rat sarcoma viral oncogene homolog in head and neck cancer: how to move forward?
Ben Yahia H; Petit FM; Saada-Bouzid E
Curr Opin Oncol; 2023 May; 35(3):178-185. PubMed ID: 36966498
[TBL] [Abstract][Full Text] [Related]
11. Tipifarnib enhances anti-EGFR activity of cetuximab in non-HRas mutated head and neck squamous cell carcinoma cancer (HNSCC).
Shu L; Wang D; Nannapaneni S; Sun Y; Griffith CC; Wang X; Chen Z; Patel M; El-Deiry M; Shin DM; Chen ZG; Saba NF
Oral Oncol; 2021 Nov; 122():105546. PubMed ID: 34700281
[TBL] [Abstract][Full Text] [Related]
12. HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.
Hah JH; Zhao M; Pickering CR; Frederick MJ; Andrews GA; Jasser SA; Fooshee DR; Milas ZL; Galer C; Sano D; William WN; Kim E; Heymach J; Byers LA; Papadimitrakopoulou V; Myers JN
Head Neck; 2014 Nov; 36(11):1547-54. PubMed ID: 24123531
[TBL] [Abstract][Full Text] [Related]
13. Whole exome sequencing uncovers HRAS mutations as potential mediators of resistance to metronomic chemotherapy.
Sambath J; Noronha V; Manda SS; Mishra R; Chandrani P; Patil V; Menon N; Chougule A; Ramachandran V; Limaye S; Kuriakose MA; Banavali SD; Kumar P; Prabhash K
Gene; 2024 Jan; 893():147952. PubMed ID: 37918550
[TBL] [Abstract][Full Text] [Related]
14. Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.
Odeniyide P; Yohe ME; Pollard K; Vaseva AV; Calizo A; Zhang L; Rodriguez FJ; Gross JM; Allen AN; Wan X; Somwar R; Schreck KC; Kessler L; Wang J; Pratilas CA
Oncogene; 2022 May; 41(21):2973-2983. PubMed ID: 35459782
[TBL] [Abstract][Full Text] [Related]
15. To Tip or Not to Tip: A New Combination for Precision Medicine in Head and Neck Cancer.
Lee RH; Johnson DE; Grandis JR
Cancer Res; 2023 Oct; 83(19):3162-3164. PubMed ID: 37779427
[TBL] [Abstract][Full Text] [Related]
16. Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers.
Untch BR; Dos Anjos V; Garcia-Rendueles MER; Knauf JA; Krishnamoorthy GP; Saqcena M; Bhanot UK; Socci ND; Ho AL; Ghossein R; Fagin JA
Cancer Res; 2018 Aug; 78(16):4642-4657. PubMed ID: 29760048
[TBL] [Abstract][Full Text] [Related]
17. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
[TBL] [Abstract][Full Text] [Related]
18. RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma.
Rampias T; Giagini A; Siolos S; Matsuzaki H; Sasaki C; Scorilas A; Psyrri A
Clin Cancer Res; 2014 Jun; 20(11):2933-46. PubMed ID: 24696319
[TBL] [Abstract][Full Text] [Related]
19. The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.
Martin D; Abba MC; Molinolo AA; Vitale-Cross L; Wang Z; Zaida M; Delic NC; Samuels Y; Lyons JG; Gutkind JS
Oncotarget; 2014 Oct; 5(19):8906-23. PubMed ID: 25275298
[TBL] [Abstract][Full Text] [Related]
20. Cooperative Genomic Lesions in HRAS-Mutant Cancers Predict Resistance to Farnesyltransferase Inhibitors.
Nigam A; Krishnamoorthy G; Chatila W; Berman K; Saqcena M; Walch H; Ho A; Schultz N; Fagin J; Untch B
Res Sq; 2023 Jul; ():. PubMed ID: 37503077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]